AbbVie announces late-breaking results from Phase III trial of HUMIRA in Hidradenitis Suppurativa patients
Data were presented as a late-breaking abstract at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) meeting in Amsterdam. The results of this study,